Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanasios Anagnostopoulos

Showing results (11-20 of 57) with videos related to

Pageof 6
Sort By:
Clinical Lymphoma & Myeloma|August 2, 2006
Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell supportEfstathios Kastritis, Evangelos Terpos, Athanasios Anagnostopoulos, et al.
Seminars in Hematology|March 16, 2004
Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, et al.
Seminars in Hematology|January 19, 2002
Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromesSergio Giralt, Athanasios Anagnostopoulos, Munir Shahjahan, et al.
British Journal of Haematology|April 29, 2006
Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemiaEvangelos Terpos, Athanasios Anagnostopoulos, Efstathios Kastritis, et al.
Annals of Hematology|July 28, 2004
Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal proteinAthanasios Anagnostopoulos, Eleni Galani, Dimitra Gika, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2005
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcomeMeletios A Dimopoulos, Vassilis L Souliotis, Athanasios Anagnostopoulos, et al.
Haematologica|September 8, 2006
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trialErsi Voskaridou, Athanasios Anagnostopoulos, Kostas Konstantopoulos, et al.
Leukemia & Lymphoma|April 6, 2004
Discordant response or progression in patients with myeloma treated with thalidomide-based regimensAthanasios Anagnostopoulos, George Hamilos, Markela P Zorzou, et al.
Leukemia & Lymphoma|April 25, 2007
Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatmentsMaria Roussou, Athanasios Anagnostopoulos, Efstathios Kastritis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myelomaJohn Koutsikos, Theodoros Athanasoulis, Athanasios Anagnostopoulos, et al.
Pageof 6

Showing results (11-20 of 57) with videos related to

Sort By:
Pageof 6
Clinical Lymphoma & Myeloma|August 2, 2006
Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell supportEfstathios Kastritis, Evangelos Terpos, Athanasios Anagnostopoulos, et al.
Seminars in Hematology|March 16, 2004
Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, et al.
Seminars in Hematology|January 19, 2002
Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromesSergio Giralt, Athanasios Anagnostopoulos, Munir Shahjahan, et al.
British Journal of Haematology|April 29, 2006
Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenström macroglobulinaemiaEvangelos Terpos, Athanasios Anagnostopoulos, Efstathios Kastritis, et al.
Annals of Hematology|July 28, 2004
Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal proteinAthanasios Anagnostopoulos, Eleni Galani, Dimitra Gika, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2005
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcomeMeletios A Dimopoulos, Vassilis L Souliotis, Athanasios Anagnostopoulos, et al.
Haematologica|September 8, 2006
Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trialErsi Voskaridou, Athanasios Anagnostopoulos, Kostas Konstantopoulos, et al.
Leukemia & Lymphoma|April 6, 2004
Discordant response or progression in patients with myeloma treated with thalidomide-based regimensAthanasios Anagnostopoulos, George Hamilos, Markela P Zorzou, et al.
Leukemia & Lymphoma|April 25, 2007
Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatmentsMaria Roussou, Athanasios Anagnostopoulos, Efstathios Kastritis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myelomaJohn Koutsikos, Theodoros Athanasoulis, Athanasios Anagnostopoulos, et al.
Pageof 6